Journal
SCIENCE
Volume 351, Issue 6268, Pages 77-81Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aad1283
Keywords
-
Categories
Funding
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek [91213066]
- Niedersachsen-Research Network on Neuroinfectiology (N-RENNT) of the Ministry of Science and Culture of Lower Saxony, Germany
- Zoonotic Anticipation and Preparedness Initiative (ZAPI project) [Innovative Medicines Initiative (IMI) grant] [115760]
- IMI
- European Commission
Ask authors/readers for more resources
Middle East respiratory syndrome coronavirus (MERS-CoV) infections have led to an ongoing outbreak in humans, which was fueled by multiple zoonotic MERS-CoV introductions from dromedary camels. In addition to the implementation of hygiene measures to limit further camel-to-human and human-to-human transmissions, vaccine-mediated reduction of MERS-CoV spread from the animal reservoir may be envisaged. Here we show that a modified vaccinia virus Ankara (MVA) vaccine expressing the MERS-CoV spike protein confers mucosal immunity in dromedary camels. Compared with results for control animals, we observed a significant reduction of excreted infectious virus and viral RNA transcripts in vaccinated animals upon MERS-CoV challenge. Protection correlated with the presence of serum neutralizing antibodies to MERS-CoV. Induction of MVA-specific antibodies that cross-neutralize camelpox virus would also provide protection against camelpox.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available